10.29.08
AMRI is expanding its multipurpose pilot plant facilities in Aurangabad, India for non-GMP manufacturing services to 1,000-liter scale capacity, which will allow the company to provide customized pilot scale materials. The new facility will serve as an extension to AMRI’s kilo lab capabilities in Hyderabad, which operates to 100 liters in scale. The plant's first production run is currently underway.
“We are pleased to offer another high value alternative to our customers seeking the cost benefit of doing business in Asia, but retaining the quality they expect from a U.S. based-organization. Separately, we look forward to realizing cost savings at our U.S. manufacturing operations by becoming our own provider for some raw materials, eliminating third party costs in both money and lead time. This expansion further demonstrates AMRI’s investment and focus in building a worldwide drug discovery and development platform,” said chairman, chief executive officer and president Thomas E. D’Ambra, Ph.D.
The company noted that certain plant production will be dedicated to making starting materials for the company’s U.S. manufacturing facilities, reducing the plant’s reliance on external resource providers.
“We are pleased to offer another high value alternative to our customers seeking the cost benefit of doing business in Asia, but retaining the quality they expect from a U.S. based-organization. Separately, we look forward to realizing cost savings at our U.S. manufacturing operations by becoming our own provider for some raw materials, eliminating third party costs in both money and lead time. This expansion further demonstrates AMRI’s investment and focus in building a worldwide drug discovery and development platform,” said chairman, chief executive officer and president Thomas E. D’Ambra, Ph.D.
The company noted that certain plant production will be dedicated to making starting materials for the company’s U.S. manufacturing facilities, reducing the plant’s reliance on external resource providers.
